Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;20(10):7350-7360.
doi: 10.1002/alz.14166. Epub 2024 Sep 11.

Overview of ADNI MRI

Clifford R Jack Jr  1 , Arvin Arani  1 , Bret J Borowski  1 , Dave M Cash  2 , Karen Crawford  3 , Sandhitsu R Das  4 , Charles DeCarli  5 , Evan Fletcher  5 , Nick C Fox  2 , Jeffrey L Gunter  1 , Ranjit Ittyerah  6 , Danielle J Harvey  7 , Neda Jahanshad  8 , Pauline Maillard  5 , Ian B Malone  2 , Talia M Nir  8 , Robert I Reid  1 , Denise A Reyes  1 , Christopher G Schwarz  1 , Matthew L Senjem  9 , David L Thomas  10 , Paul M Thompson  3 , Duygu Tosun  11 , Paul A Yushkevich  6 , Chadwick P Ward  1 , Michael W Weiner  11 ; Alzheimer's Disease Neuroimaging Initiative
Affiliations
Review

Overview of ADNI MRI

Clifford R Jack Jr et al. Alzheimers Dement. 2024 Oct.

Abstract

The magnetic resonance imaging (MRI) Core has been operating since Alzheimer's Disease Neuroimaging Initiative's (ADNI) inception, providing 20 years of data including reliable, multi-platform standardized protocols, carefully curated image data, and quantitative measures provided by expert investigators. The overarching purposes of the MRI Core include: (1) optimizing and standardizing MRI acquisition methods, which have been adopted by many multicenter studies and trials worldwide and (2) providing curated images and numeric summary values from relevant MRI sequences/contrasts to the scientific community. Over time, ADNI MRI has become increasingly complex. To remain technically current, the ADNI MRI protocol has changed substantially over the past two decades. The ADNI 4 protocol contains nine different imaging types (e.g., three dimensional [3D] T1-weighted and fluid-attenuated inversion recovery [FLAIR]). Our view is that the ADNI MRI data are a greatly underutilized resource. The purpose of this paper is to educate the scientific community on ADNI MRI methods and content to promote greater awareness, accessibility, and use. HIGHLIGHTS: The MRI Core provides multi-platform standardized protocols, carefully curated image data, and quantitative analysis by expert groups. The ADNI MRI protocol has undergone major changes over the past two decades to remain technically current. As of April 25, 2024, the following numbers of image series are available: 17,141 3D T1w; 6877 FLAIR; 3140 T2/PD; 6623 GRE; 3237 dMRI; 2846 ASL; 2968 TF-fMRI; and 2861 HighResHippo (see Table 1 for abbreviations). As of April 25, 2024, the following numbers of quantitative analyses are available: FreeSurfer 10,997; BSI 6120; tensor based morphometry (TBM) and TBM-SYN 12,019; WMH 9944; dMRI 1913; ASL 925; TF-fMRI NFQ 2992; and medial temporal subregion volumes 2726 (see Table 4 for abbreviations). ADNI MRI is an underutilized resource that could be more useful to the research community.

Keywords: ADNI; Alzheimer's disease MRI; Alzheimer's disease imaging; magnetic resonance imaging.

PubMed Disclaimer

Conflict of interest statement

Arvin Arani, Bret Borowski, Evan Fletcher, Nick Fox, Jeffrey Gunter, Ranjit Ittyerah, Neda Jahanshad, Pauline Maillard, Robert Reid, Denise Reyes, and Matthew Senjem have nothing to disclose. Dave Cash has nothing to disclose. He is supported by the UK Dementia Research Institute, which receives its funding from DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK, Alzheimer's Association (SG‐666374‐UK BIRTH COHORT), and the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre. He is also partly funded under NIH/ADNI 4 grant through the money Nick Fox receives for his work. Karen Crawford has no funding interests to disclose. Sandhitsu Das has no relevant disclosures. He receives funding for AG072796. Charles DeCarli receives funding from U01 AG024904, P30 AG072972. He has no conflicts. Dr. Harvey receives research funding from the NIH, related and unrelated to this work, and serves as statistical advisor to PLOS ONE. Ian B. Malone is supported by grants to his institution from NIH and is an employee of the Dementia Research Centre, which is supported by Alzheimer's Research UK, Brain Research Trust, and The Wolfson Foundation. Talia Nir has nothing to disclose. Funding from AARG‐23‐1149996. Dr. Schwarz receives research funding from the NIH (R01 AG068206), related and unrelated to this study. David L. Thomas is supported by the UCLH NIHR Biomedical Research Centre. He has no conflicts or disclosures. Paul Thompson was supported in part by the National Institute on Aging (NIA) grant RF1 AG057892. He has no disclosures. Duygu Tosin receives grant funding from the National Institutes of Health. Paul Yushkevich has nothing to disclose. His major grants are RF1 AG056014, RF1 AG069474, P30 AG072979. Chadwick Ward has no conflicts. Dr. Weiner serves on editorial boards for Alzheimer's & Dementia and the Journal for Prevention of Alzheimer's Disease (JPAD). He has served on advisory boards for Acumen Pharmaceutical, Alzheon, Inc., Amsterdam UMC; MIRIADE, Cerecin, Merck Sharp & Dohme Corp., NC Registry for Brain Health, and REGEnLIFE. He also serves on the USC ACTC grant, which receives funding from Eisai. He has provided consulting to Boxer Capital, LLC, Cerecin, Inc., Clario, Dementia Society of Japan, Dolby Family Ventures, Eisai, Guidepoint, Health and Wellness Partners, Indiana University, LCN Consulting, MEDA Corp., Merck Sharp & Dohme Corp., NC Registry for Brain Health, Prova Education, T3D Therapeutics, University of Southern California (USC), and WebMD. He has acted as a speaker/lecturer for China Association for Alzheimer's Disease (CAAD) and Taipei Medical University, as well as a speaker/lecturer with academic travel funding provided by: AD/PD Congress, Amsterdam UMC, Cleveland Clinic, CTAD Congress, Foundation of Learning; Health Society (Japan), Kenes, U. Penn, U. Toulouse, Japan Society for Dementia Research, Korean Dementia Society, Merck Sharp & Dohme Corp., National Center for Geriatrics and Gerontology (NCGG; Japan), and University of Southern California (USC). He holds stock options with Alzeca, Alzheon, Inc., ALZPath, Inc., and Anven. Dr. Weiner received support for his research from the following funding sources: National Institutes of Health (NIH)/NINDS/National Institute on Aging (NIA), Department of Defense (DOD), California Department of Public Health (CDPH), University of Michigan, Siemens, Biogen, Hillblom Foundation, Alzheimer's Association, Johnson & Johnson, Kevin and Connie Shanahan, GE, VUmc, Australian Catholic University (HBI‐BHR), The Stroke Foundation, and the Veterans Administration. Author disclosures are available in the Supporting information.

References

    1. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid‐related imaging abnormalities in amyloid‐modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367‐385. - PMC - PubMed
    1. Stoker TB, Andresen KER, Barker RA. Hydrocephalus complicating intrathecal antisense oligonucleotide therapy for Huntington's disease. Mov Disord. 2021;36:263‐264. - PMC - PubMed
    1. Kwon D. Genetic therapies offer new hope against incurable brain diseases. Nature. 2021;592:180‐183. - PubMed
    1. Bennett CF, Krainer AR, Cleveland DW. Antisense oligonucleotide therapies for neurodegenerative diseases. Annu Rev Neurosci. 2019;42:385‐406. - PMC - PubMed
    1. Leavitt BR, Tabrizi SJ. Antisense oligonucleotides for neurodegeneration. Science. 2020;367:1428‐1429. - PubMed

MeSH terms